rh Growth Hormone

Small molecule

NNational Human Genome Research Institute (NHGRI)

rh Growth Hormone is one of 9 small molecule programs targeting Cystinosis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CystinosisActive, not recruiting

CystinosisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Cystinosis

#DrugCompanyPhaseTrials

Acetadote

AArbor Pharmaceuticals, Inc.

N-Acetyl Cyteien

1 3

RP103

Amgen

Phase 3

3 4

Cystagon

Amgen

Phase 2

3 5

ELX-02

EEloxx Pharmaceuticals, Inc.

Phase 2

1 6

Cystadrops

LLeadiant Biosciences, Inc.

Preclinical

3 7

Procysbi

HHorizon Therapeutics Ireland DAC

Preclinical

3 8

N-Acetylcysteine Amide

NNacuity Pharmaceuticals, Inc.

Preclinical

1 9

rh Growth Hormone

NNational Human Genome Research Institute (NHGRI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystinosis1 trial

Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis

Withdrawn·NNational Human Genome Research Institute (NHGRI)·Phase 1/2·NCT02124070

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for rh Growth Hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rh Growth Hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rh Growth Hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Human Genome Research Institute (NHGRI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: NNational Human Genome Research Institute (NHGRI)

rh Growth Hormone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystinosis1 trial

References

Drug Info

Quick Facts

Related News